Clinical data | |
---|---|
Pronunciation | /pɪˈtɒlɪsənt/ pi-TOL-i-sənt |
Trade names | Wakix, Ozawade |
Other names | Tiprolisant; Ciproxidine; BF2.649 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a619055 |
License data |
|
Routes of administration | By mouth |
Drug class | Histamine H3 receptor inverse agonist |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 10–12 hours |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H26ClNO |
Molar mass | 295.85 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Pitolisant, sold under the brand name Wakix among others, is a medication used for the treatment of excessive daytime sleepiness in adults with narcolepsy.[3] It is an inverse agonist of the histamine 3 (H3) receptor (an antihistamine drug specific to that kind of receptors).[3] It represents the first commercially available medication in its class, so that the U.S. Food and Drug Administration (FDA) declares it a first-in-class medication.[7][8] Pitolisant enhances the activity of histaminergic neurons in the brain that function to improve a person's wakefulness.[9] It was approved by the European Medicines Agency (EMA) in March 2016 for narcolepsy with or without cataplexy, and for excessive daytime sleepiness by the FDA in August 2019.[10] The most common side effects include difficulty sleeping, nausea, and feeling worried.[11]
Wakix EPAR
was invoked but never defined (see the help page).Ozawade EPAR
was invoked but never defined (see the help page).FDA snapshot
was invoked but never defined (see the help page).